Risultati della ricerca - Allison Crosby‐Thompson

  • Mostra 1 - 4 risultati su 4
Raffina i risultati
  1. 1
    Radiation for diffuse large <scp>B</scp>‐cell lymphoma in the rituximab era: Analysis of the <scp>N</scp>ational <scp>C</scp>omprehensive <scp>C</scp>ancer <scp>N</scp>etwork lymphoma outcomes project

    Radiation for diffuse large <scp>B</scp>‐cell lymphoma in the rituximab era: Analysis of the <scp>N</scp>ational <scp>C</scp>omprehensive <scp>C</scp>ancer <scp>N</scp>etwork lymph... di Bouthaina S. Dabaja, Ann Vanderplas, Allison Crosby‐Thompson, Gregory A. Abel, Myron S. Czuczman, Jonathan W. Friedberg, Leo I. Gordon, Mark Kaminski, Joyce C. Niland, Michael Millenson, Auayporn Nademanee, Andrew D. Zelenetz, Ann S. LaCasce, Maria Alma Rodriguez

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the <scp>NCCN</scp> outcomes database

    Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the <scp>NCCN</scp> outcomes database di Makiko Ban‐Hoefen, Ann Vanderplas, Allison Crosby‐Thompson, Gregory A. Abel, Myron S. Czuczman, Leo I. Gordon, Mark Kaminski, Jennifer L. Kelly, Michael Millenson, Auayporn Nademanee, Maria Alma Rodriguez, Andrew D. Zelenetz, Joyce C. Niland, Ann S. LaCasce, Jonathan W. Friedberg

    Pubblicazione 2013
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma

    KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma di Katherine N. Cahill, Howard R. Katz, Jing Cui, Juying Lai, Shamsah Kazani, Allison Crosby‐Thompson, Denise Garofalo, Mario Castro, Nizar N. Jarjour, Emily DiMango, Serpil C. Erzurum, Jennifer Trevor, Kartik Shenoy, Vernon M. Chinchilli, Michael E. Wechsler, Tanya M. Laidlaw, Joshua A. Boyce, Elliot Israel

    Pubblicazione 2017
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

    An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era di Zheng Zhou, Laurie H. Sehn, Alfred Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby‐Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria Alma Rodriguez, Auayporn Nademanee, Mark Kaminski, Myron S. Czuczman, Michael Millenson, Joyce C. Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg, Jane N. Winter

    Pubblicazione 2013
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: